Study of Cabozantinib Plus TAS102 in mCRC as Salvage Therapy

ABSTRACT: This is a phase I clinical trial assessing the safety and recommended phase II dose of cabozantinib in combination with trifluridine/tipiracil (TAS102) in patients with metastatic colorectal carcinoma (mCRC).

DISEASE(S): Colorectal Carcinoma,Crc,Colorectal Cancer,Colorectal Neoplasms,Metastatic Cancer

PROVIDER: 2376141 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR